US Patent

US10487111 — IBAT inhibitors for the treatment of liver diseases

Method of Use · Assigned to Albireo AB · Expires 2031-11-08 · 5y remaining

Vulnerability score 51/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects specific IBAT inhibitors for use in the prophylaxis and/or treatment of liver diseases.

USPTO Abstract

The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.

Drugs covered by this patent

Bylvay (ODEVIXIBAT) · Ipsen

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3186`	—	Bylvay
`U-3186`	—	Bylvay
`U-3186`	—	Bylvay
`U-3186`	—	Bylvay

Patent Metadata

Patent number: US10487111
Jurisdiction: US
Classification: Method of Use
Expires: 2031-11-08
Drug substance claim: No
Drug product claim: No
Assignee: Albireo AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.